Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm
- PMID: 26396535
- PMCID: PMC4576896
- DOI: 10.2147/IDR.S87224
Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm
Abstract
Treatment options for Clostridium difficile infection (CDI) remain limited despite this usually nosocomial infection posing an urgent threat to public health. A major paradox of the management of CDI is the use of antimicrobial agents to treat infection, which runs the risk of prolonged gut microbiota perturbation and so recurrence of infection. Here, we explore alternative CDI treatment and prevention options currently available or in development. Notably, strategies that aim to reduce the negative effects of antibiotics on gut microbiota offer the potential to alter current antimicrobial stewardship approaches to preventing CDI.
Keywords: CDI; SYN-004; beta-lactams; prevention; treatment; vaccine.
References
-
- Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control. 2014;42(10):1028–1032. - PubMed
-
- Hall IC, O’Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390–402.
-
- Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis. 1994;18(Suppl 4):S265–S272. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous